大博集团品牌怎么样 申请店铺

我要投票 大博集团在男科医院行业中的票数:364 更新时间:2025-08-12
大博集团是哪个国家的品牌?「大博集团」是 大博医疗科技股份有限公司 旗下著名品牌。该品牌发源于福建省厦门市,由创始人林 * 雄在2004年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力大博集团品牌出海!将品牌入驻外推网,定制大博集团品牌推广信息,可以显著提高大博集团产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

大博集团怎么样

成立于2004年,以骨科、神经外科、微创外科为主的综合性医疗集团,与世界各地的专家建立良好的合作关系和经验交流


大博简介

大博医疗科技股份有限公司,成立于2004年,坐落于美丽的鹭岛——厦门,是一家以骨科、神经外科、微创外科为主的综合性医疗集团。公司先后通过了FDA、CE、ISO13485、GMP等专业认证,产品品质不断超越国际标准,得到国内外用户的一致认可。

研发制造

紧密结合临床,是大博开展研发工作的基石。经多年的钻研沉淀,与国内北上广等地的知名专家,以及澳大利亚、瑞士等国际专家,皆建立起良好的合作关系,广纳临床专家的实践经验,坚持不懈地进行产品和技术的提升与创新。同时,大博成立了厦门骨科医疗器械工程技术研究中心、与厦门大学联合成立厦大化工——大博医疗外科材料研发中心、同时还与台湾科技大学合办产学研项目,并承接多个科技项目。引进国际加工设备,以高度机械化的生产工艺,依托科学的质量管理体系,精心打造各种医疗产品,涵盖骨科、齿科、微创外科、神经外科、医用电子、医疗设备等。

营销网络

大博在产品、推广、服务等各方面进行创新,在全国多省均设有物流平台,构建便捷的物流网络。与近千家经销商通力合作,不断提高服务效率,及时地为3500余家医院提供优质的服务。同时,大博设立专业的“咨询服务与技术支持”团队,为客户提供医疗器械使用方法及技术要点咨询服务,解决医师在临床上遇到的困难和问题。“高品质,赢天下”。大博放眼全球,实行国际化战略布局,拥有涵盖英语、俄语、拉丁语等多语种的国际营销部门,产品直接出口至澳大利亚、瑞士、俄罗斯、乌克兰等20多个国家和地区。

发展战略

为配合企业前进的步伐,大博制定了四化发展战略:专业化——专攻医疗产品,只做业内前三;多元化——在医疗领域内实现产品多元化,打造综合性医用高值材料供应商;国际化——国际化发展战略,产品研发销售皆面向国际市场;创新化——产品研发、企业发展立足创新,推出创新性医疗产品,坚持以创新驱动发展企业。进行以产品为核心的研发、制造、教育、推广。


Founded in 2004, a comprehensive medical group focusing on orthopedics, neurosurgery and minimally invasive surgery, established a good cooperation relationship and experience exchange with experts from all over the world. Dabo Medical Technology Co., Ltd., founded in 2004, is located in Xiamen, the beautiful island of heron. It is a comprehensive medical group focusing on orthopedics, neurosurgery and minimally invasive surgery. The company has passed FDA, CE, ISO13485, GMP and other professional certification. The product quality continues to exceed international standards, and has been unanimously recognized by users at home and abroad. R & D and manufacturing are closely combined with clinical practice, which is the cornerstone of Dabo's R & D work. After years of research and precipitation, we have established good cooperation with well-known experts in China, Beijing, Shanghai, Guangzhou and other places, as well as international experts in Australia, Switzerland and other places. We have widely accepted the practical experience of clinical experts, and have been unremitting in product and technology upgrading and innovation. At the same time, Dabo has established Xiamen orthopedic medical device engineering technology research center, Xiamen University and Xiamen University to jointly establish Xiamen University chemical - Dabo medical surgical material research and development center. At the same time, Dabo and Taiwan University of science and technology jointly run production, teaching and research projects, and undertake a number of scientific and technological projects. With the introduction of international processing equipment, highly mechanized production process, and relying on scientific quality management system, we have carefully built various medical products, including orthopedics, dentistry, minimally invasive surgery, neurosurgery, medical electronics, medical equipment, etc. The marketing network is innovative in products, promotion, services and other aspects. It has logistics platforms in many provinces across the country to build a convenient logistics network. Cooperate with nearly 1000 distributors to improve service efficiency and provide quality services to more than 3500 hospitals in a timely manner. At the same time, Dabo has set up a professional "consulting service and technical support" team to provide customers with consulting services on the use methods and technical points of medical devices, so as to solve the clinical difficulties and problems encountered by doctors. "High quality, win the world". Dabo has a global perspective and an international strategic layout. It has an international marketing department covering English, Russian, Latin and other languages. Its products are directly exported to more than 20 countries and regions, including Australia, Switzerland, Russia, Ukraine and so on. Development strategy in line with the pace of enterprise progress, Dabo has formulated four development strategies: Specialization - specializing in medical products, only making the top three in the industry; diversification - realizing product diversification in the medical field, creating comprehensive medical high-value material suppliers; internationalization - international development strategy, product R & D and sales are oriented to the international market; innovation - Product R & D Based on innovation, the development of enterprises will launch innovative medical products and adhere to innovation driven development of enterprises. Carry out R & D, manufacturing, education and promotion with products as the core.

本文链接: https://brand.waitui.com/2fe6bfaf5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

巴西称美方取消两国财长视频会议

当地时间8月11日,巴西财政部长哈达德透露,原定13日与美国财政部长贝森特就巴西产品关税问题举行的视频会议已被美方取消,目前新的会议日期尚未确定。哈达德在接受采访时表示,巴西政府计划为巴西企业推出融资、公共采购和税务分析三项临时举措,以应对美加征关税影响。(央视新闻)

38分钟前

科技创新债发行扩容,热度有望延续

今年5月,中国人民银行、中国证监会联合发布关于支持发行科技创新债券有关事宜的公告。公告发布后,科技创新债市场快速扩容,发行只数、发行规模较去年同期激增,政策落地效果显著。专家表示,科技创新债有望迎来更多供给,还需从推动债券条款创新、丰富增信措施等方面入手,提升投资者对民营企业科技创新债的认可度,提高发债成功率。(中证报)

38分钟前

券商年内已宣布撤销87家分支机构

近年来,随着投资者的业务办理逐渐向线上转移,叠加降本增效目标的驱动,券商密集对旗下营业部、子公司等分支机构进行撤销或合并,以优化资源配置。据统计,截至8月11日,年内券商已宣布撤销87家分支机构。“券商对线下分支机构进行整合、精简,是节约经营成本、提升展业效率的要求,也是互联网时代行业发展的必然趋势。”盘古智库(北京)信息咨询有限公司高级研究员余丰慧表示。(证券日报)

38分钟前

华泰证券:建议关注新疆板块投资机会

36氪获悉,华泰证券研报认为,近日国家铁路集团注册资本950亿元成立新藏铁路公司,新藏铁路建设预计对应总投资2000亿元—5000亿元,和田至省界段已于2025年5月启动土石方招投标,此次专业公司成立标志项目稳步推进。华泰证券认为新疆在能源、资源、地缘优势下战略地位突出,政策高度重视区域发展,随着疆内产业发展、重大基建落地,有望迎来加速发展。同时短期自治区成立70周年或继续成为市场重要催化之一,建议关注新疆板块投资机会。

38分钟前

2025年并购重组市场明显提速,呈现四大新特征

2025年以来,并购重组市场明显提速,涉及公司数量显著增加。从大背景来看,无论是政策端的大力推动,还是市场主体的积极参与,都使得并购重组愈发活跃。数据显示,本轮并购重组浪潮呈现四大特征:规模更大、双创公司占比高、政策包容性更强、聚焦产业整合。这些新特征有望对各个行业的竞争格局进行重塑,并为经济的高质量发展注入全新活力。(证券时报)

38分钟前

本页详细列出关于大博集团的品牌信息,含品牌所属公司介绍,大博集团所处行业的品牌地位及优势。
咨询